Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.03 -2.5%	$3.16	$1.14 ▼ $7.20	$309.06M	0.9	889,531 shs	1.92 million shs
ARDX Ardelyx	$4.52 -1.7%	$3.92	$3.21 ▼ $7.18	$1.10B	0.6	4.42 million shs	2.66 million shs
AUPH Aurinia Pharmaceuticals	$9.07 +2.5%	$8.12	$5.20 ▼ $10.67	$1.20B	1.16	1.41 million shs	1.96 million shs
ELVN Enliven Therapeutics	$23.34 +8.8%	$19.93	$13.30 ▼ $30.03	$1.05B	0.83	305,562 shs	792,116 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+3.82%	+14.16%	+70.86%	+135.62%	+20.00%
ARDX Ardelyx	+2.22%	0.00%	+25.68%	-4.56%	-25.93%
AUPH Aurinia Pharmaceuticals	-1.56%	+5.48%	+8.72%	+14.02%	+52.59%
ELVN Enliven Therapeutics	-0.88%	-0.56%	-7.06%	+29.82%	-12.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.385 of 5 stars	3.5	3.0	0.0	2.2	0.8	0.6
ARDX Ardelyx	4.1034 of 5 stars	3.5	1.0	4.4	2.6	2.5	0.6
AUPH Aurinia Pharmaceuticals	3.2889 of 5 stars	3.5	2.0	0.0	3.8	0.8	1.9
ELVN Enliven Therapeutics	2.8344 of 5 stars	3.5	2.0	0.0	2.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	88.87% Upside
ARDX Ardelyx	3.00	Buy	$10.89	140.90% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	26.79% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	76.52% Upside

Current Analyst Ratings Breakdown

Latest ALDX, AUPH, ARDX, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
ARDX Ardelyx	$333.61M	3.24	N/A	N/A	$0.73 per share	6.19
AUPH Aurinia Pharmaceuticals	$235.13M	5.21	$0.32 per share	28.69	$2.68 per share	3.38
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.22	N/A	14.58	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	32.39	16.20	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)

Latest ALDX, AUPH, ARDX, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ARDX Ardelyx	-$0.12	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
ARDX Ardelyx	1.04	4.12	3.81
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
ELVN Enliven Therapeutics	N/A	21.07	21.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ARDX Ardelyx	58.92%
AUPH Aurinia Pharmaceuticals	36.83%
ELVN Enliven Therapeutics	95.08%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
ARDX Ardelyx	4.80%
AUPH Aurinia Pharmaceuticals	12.20%
ELVN Enliven Therapeutics	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.15 million	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable

ALDX, AUPH, ARDX, and ELVN Headlines

Recent News About These Companies

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 5.7% - Here's What Happened

July 15 at 4:23 PM | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,660.00 in Stock

July 15 at 4:42 AM | insidertrades.com

Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

July 14 at 7:19 PM | marketbeat.com

Enliven Therapeutics Breaks Above 200-Day Moving Average - Nasdaq

July 12, 2025 | nasdaq.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Buy" from Brokerages

July 11, 2025 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Buy" from Brokerages

July 11, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

July 9, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.4% Higher - What's Next?

July 9, 2025 | marketbeat.com

Q2 EPS Forecast for Enliven Therapeutics Boosted by Analyst

July 4, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade

July 2, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says

July 2, 2025 | marketbeat.com

Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

July 2, 2025 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

July 1, 2025 | marketbeat.com

Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?

June 30, 2025 | tipranks.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

June 24, 2025 | marketbeat.com

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

June 23, 2025 | msn.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in Stock

June 18, 2025 | marketbeat.com

Goldman Sachs initiates Enliven Therapeutics stock with Buy rating

June 17, 2025 | investing.com

Enliven grosses $230M from stock sale

June 17, 2025 | bizwest.comB

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

June 17, 2025 | msn.com

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

June 16, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, AUPH, ARDX, and ELVN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.03 -0.13 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$5.06 +0.02 (+0.50%)

As of 07:51 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Ardelyx NASDAQ:ARDX

$4.52 -0.08 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$4.51 0.00 (-0.11%)

As of 07:50 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$9.07 +0.22 (+2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$9.03 -0.04 (-0.44%)

As of 07:59 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Enliven Therapeutics NASDAQ:ELVN

$23.34 +1.88 (+8.76%)

Closing price 04:00 PM Eastern

Extended Trading

$23.37 +0.03 (+0.15%)

As of 07:19 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time